Lung

, Volume 181, Issue 6, pp 329–334

Endostatin Levels in Exudative Pleural Effusions

  • M. Sumi
  • K. Kagohashi
  • H. Satoh
  • H. Ishikawa
  • Y. Funayama
  • K. Sekizawa
Article

Abstract

Endostatin is an angiogenesis inhibitor that is an endogenously produced proteolytic fragment of type XVIII collagen. Although serum levels of endostatin have extensively been studied in patients with malignant diseases, endostatin in pleural effusion has not been fully evaluated. In order to determine whether endostatin is present in pleural effusion, and to determine whether endostatin levels vary in pleural effusion of different etiology, we measured levels of endostatin in 38 malignant pleural effusion due to lung cancer patients and 29 patients with non-malignant disease using an ELISA kit. Free form of endostaitn was measurable (>11.2 pg/ml) in 26 of 38 malignant and 13 of 29 non-malignant pleural effusion. Endostatin levels in the 38 malignant pleural effusion were significantly higher than those in patients with the 29 patients with non-malignant diseases (p = 0.0131). However, there was not statistically significant difference between the patients with pleuropneumonia and those with tuberculous pleurisy (p = 0.2194). In malignant pleural effusion due to lung cancer, the pleural effusion endostatin levels did not differ when the histological types of lung cancer were considered(p = 0.0674). Endostatin was present in both malignant and non-malignant pleural effusion, and elevated levels of endostatin were observed in malignant pleural effusion. Although the mechanisms are unclear, elevated levels of endostatin in pleural effusion may represent the local productions of endostatin in pleural space.

Keywords

Pleural effusion Endostatin Lung cancer Tuberculosis Pleuropneumonia 

References

  1. 1.
    Feldman, AL, Tamarkin, L, Paciotti, GF, Simpson, BW, Linehan, WM, Yang, JC 2000Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage VI renal cancer.Clin Cancer Res646284634PubMedGoogle Scholar
  2. 2.
    Fenton, KN, Richardson, JD 1995Diagnosis and management of malignant pleural effusions.Am J Surg1706974CrossRefPubMedGoogle Scholar
  3. 3.
    Garcia-Pachon, E, Llorca, I 2002Diagnostic value of C-reactive protein in exudative pleural effusions.Eur J Intern Med13246249CrossRefPubMedGoogle Scholar
  4. 4.
    Hebbar, M, Peyrat, J, Hornez, L, Hatron, P, Hachulla, E, Devulder, B 2000Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis.Arthritis Rhem43889893CrossRefGoogle Scholar
  5. 5.
    Helfer, L, Tempfer, C, Kainz, C, Obermair, A 1999Serum concentrations of endostatin in patients with vulvar cancer.Gynecol Oncol74151152CrossRefPubMedGoogle Scholar
  6. 6.
    Homer, JJ, Greenman, J, Stafford, ND 2002Circulating angiogenic cytokines as tumor markers and prognostic factors in head and neck squamous cell carcinoma.Clin Otolaryngol273237CrossRefPubMedGoogle Scholar
  7. 7.
    Miyashita, M, Tajiri, T, Yanagi, K, Shimizu, T, Futami, R, Sasajima, K, Tokunaga, A 2003Serum levels of vascular endothelial growth factor, basic fibroblast growth factor and endostatin in human metastatic liver tumors.Hepatogastroenterology50308309PubMedGoogle Scholar
  8. 8.
    Naito, T, Satoh, H, Ishikawa, H, Yamashita, YT, Kamma, H, Takahashi, H, Hasegawa, S 1997Pleural effusion as a significant prognostic factor in non-small cell lung cancer.Anticancer Res1747434746PubMedGoogle Scholar
  9. 9.
    Qin, LX, Tang, ZY 2002The prognostic molecular markers in hepatocellular carcinoma.World J Gastroenterol8385392PubMedGoogle Scholar
  10. 10.
    Satoh, H, Sumi, M, Yagyu, H, Ishikawa, H, Suyama, T, Naitoh, T, Saitoh, T, Hasegawa, S 1995Clinical evaluation of CYFRA 21-1 in malignant pleural fluids.Oncology53211214Google Scholar
  11. 11.
    Shaarawy, M, El-Sharkawy, SA 2001Biomarkers of intrinsic angiogenic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer.Acta Oncol40513518CrossRefPubMedGoogle Scholar
  12. 12.
    Suzuki, M, Iizasa, T, Ko, E, Baba, M, Saitoh, Y, Shibuya, K 2002Serum endostatin correlates with progression and prognosis of non-small cell lung cancer.Lung Cancer352934CrossRefPubMedGoogle Scholar
  13. 13.
    Tamura, S, Nishigaki, T, Moriwaki, Y, Fujioka, H, Nakano, T, Fujii, J, Yamamoto, T, Nabeshima, K, Hada, T, Higashino, K 1988Tumor markers in pleural effusion diagnosis.Cancer61298302PubMedGoogle Scholar
  14. 14.
    van Hensbergen, Y, Broxterman, HJ, Hanemaaijer, R, Jorna, AS, van Lent, NA, Verheul, HMW, Pinedo, HM, Hoekman, K 2002Soluble aminopeptidase N/CD 13 in malignant and nonmalignant effusions and intratumoral fluid.Clin Cancer Res837473754PubMedGoogle Scholar
  15. 15.
    Wu, P, Yonekura, H, Li, H, Nosaki, I, Tomono, Y, Naito, I, Nimomiya, Y, Yamamoto, H 2001Hypoxia down-regulates endostatin production by human microvascular endothelial cells and pericytes.Biochem Biophys Res Commun28811491154PubMedGoogle Scholar
  16. 16.
    Yamagata, M, Shiratori, Y, Dan, Y, Shiina, S, Takayama, T, Makuuchi, M, Omata, M 2000Serum endostatin levels in patients with hepatocellular carcinoma.Ann Oncol11761762PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 2003

Authors and Affiliations

  • M. Sumi
    • 1
  • K. Kagohashi
    • 1
  • H. Satoh
    • 1
  • H. Ishikawa
    • 1
  • Y. Funayama
    • 1
  • K. Sekizawa
    • 1
  1. 1.Division of Respiratory Medicine, Institute of Clinical MedicineUniversity of Tsukuba, Tsukuba-City, Ibaraki 305-8575 Japan

Personalised recommendations